Nipro books FX loss but gains subsidy for new antibiotic plant

Nipro ( (JP:8086) ) has issued an update.

Nipro Corporation reported that it booked ¥4.19 billion in foreign exchange losses as non-operating expenses for the fiscal year ended March 31, 2026, reflecting currency fluctuations over the period. At the same time, a subsidiary’s project to build a new manufacturing facility for cephalosporin antibiotic dual-chamber bag formulations at the Omi Plant qualified for a government program to strengthen supply chains, underscoring Nipro’s strategic investment in domestic production capacity.

Following approval under the Ministry of Economy, Trade and Industry’s supply chain investment program, Nipro recognized ¥4.07 billion in subsidy income and, under compression accounting, recorded a related ¥3.87 billion extraordinary loss on fixed asset reduction. These items have already been incorporated into the company’s consolidated financial results under Japan GAAP, signaling a one-off impact on earnings while supporting longer-term manufacturing resilience and supply stability for stakeholders.

The most recent analyst rating on (JP:8086) stock is a Hold with a Yen1500.00 price target. To see the full list of analyst forecasts on Nipro stock, see the JP:8086 Stock Forecast page.

More about Nipro

Nipro Corporation is a Japan-based medical manufacturer focused on pharmaceuticals, medical devices, and related healthcare products, with operations spanning domestic and international markets. The company emphasizes manufacturing capabilities in areas such as injectable drugs and infusion-related products, including advanced formulations and packaging technologies for hospital and clinical use.

Average Trading Volume: 711,980

Technical Sentiment Signal: Buy

Current Market Cap: Yen240.6B

Find detailed analytics on 8086 stock on TipRanks’ Stock Analysis page.